Does the PD-L1 Level Determine Lung Cancer Immunotherapy Outcomes? (2026 Update)

The level of PD-L1 expression is one of the key markers that can differ immunotherapy response, but it is never the sole deciding factor — histologic type, MSI status, and overall condition are reviewed together before a treatment decision is made.

Key Takeaways

• Immune checkpoint inhibitors work by blocking PD-1/PD-L1 signaling so that immune cells can attack cancer again, and the degree of PD-L1 expression is a representative marker used to select this treatment (National Cancer Center Korea).
• In stage IV non-small cell lung cancer without an actionable target such as EGFR or ALK, PD-L1 expression and histologic type are reviewed together to decide between checkpoint inhibitor monotherapy or combination with chemotherapy.
• When MSI-High or MMR deficiency is confirmed, immunotherapy response tends to be favorable regardless of the primary tumor site, so this marker is checked alongside PD-L1.
• When PD-L1 expression is low and the tumor has a character that keeps immune cells from infiltrating it, efficacy is described as being reduced.
• Response is typically assessed by CT every 2–3 months, and no treatment can promise a specific individual outcome in advance.

What Is PD-L1 Expression, and Why Does It Matter?

• PD-L1 is a signaling protein that some cancer cells display on their surface to press the brake on T-cell attack. The more of this signal a cancer cell produces, the more likely immune cells will pass it by even when standing right next to it.
• Immune checkpoint inhibitors block the connection between the PD-1 switch and the PD-L1 signal, releasing that brake. For this reason, the PD-L1 expression level is a core test used to gauge how likely a drug is to work, and it is confirmed through tissue testing.
• In lung cancer, genetic alterations such as EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, and NTRK must be checked together with PD-L1 expression to determine which drug should be tried first. NGS testing, which examines multiple genes at once, is commonly used for this purpose.

What Else Is Checked Besides PD-L1?

• PD-L1 expression alone does not determine treatment. Markers such as MSI-High or MMR deficiency and tumor mutational burden are reviewed together, and which markers matter varies by cancer type.
• In stage IV non-small cell lung cancer, if a target such as EGFR or ALK is present, oral targeted therapy is considered first. When no target is present, PD-L1 expression and histologic type are reviewed to decide whether to start a checkpoint inhibitor alone or combined with chemotherapy.
• For patients with an autoimmune disease, those on immunosuppressants after an organ transplant, or those on high-dose steroids, the decision is made cautiously regardless of the PD-L1 level.

What Is the Process From Testing to Response Assessment?

• Step 1: A tissue biopsy confirms histologic type along with markers such as PD-L1 and MSI/MMR status. If the tissue sample is old or insufficient, a repeat biopsy may be needed.
• Step 2: Once the drug is selected, it is given by IV infusion, with an interval of 2, 3, or 6 weeks depending on the agent. For the first dose, admission or a one-day observation period is recommended to monitor for a reaction.
• Step 3: Response is typically assessed by CT every 2–3 months. In some cases, the tumor appears larger on early imaging before later shrinking, so conclusions are not drawn from a single scan.
• Step 4: If the treatment is working and side effects are tolerable, continuing for anywhere from several months up to 2 years is the general pattern, with the attending medical team determining the stopping point based on cancer type, response, and side effects.

FAQ — If PD-L1 Is Low, Does That Rule Out Immunotherapy Entirely?

When PD-L1 expression is low and the tumor's character keeps immune cells from infiltrating it, efficacy is described as reduced. However, if another marker such as MSI-High is also confirmed, response can still be favorable, so markers are judged together rather than in isolation. When immunotherapy is not a good fit, targeted therapy or chemotherapy become alternative options.

FAQ — Do I Need to Repeat the PD-L1 Test After Arriving?

If testing was already done at home, those results can typically be used as is. If no results exist, the results are old, or certain items are missing, options include sending tissue slides or paraffin blocks for NGS testing in Korea, or repeating testing after arrival. It is best to prepare a report that includes both the testing method and the criteria used for interpretation.

Sources and Notes

• This article was written based on notes regarding immunotherapy, lung cancer, targeted therapy, and pre-treatment checklists (National Cancer Center Korea, NCCN patient guidelines, National Cancer Registration Statistics 2019–2023, National Cancer Center Korea Central Cancer Registry, SEER).
• This content is intended for general medical information purposes only, and actual diagnosis, treatment methods, and outcomes may vary by individual condition. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.